Skip to main content

Labcorp Holdings Inc. (LH) Stock Analysis

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Diagnostics & Research

Sell if holding. Momentum 1.3/10 is below the 5.0 floor at $255.89 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Thin upside margin: 9.0%.

Labcorp Holdings is a global laboratory services company with nearly 71,000 employees serving approximately 100 countries, performing 750M+ tests annually in 2025. Revenue is from diagnostic testing (Dx) billed to third-party payors and biopharma laboratory services (BLS)... Read more

$255.89+9.0% A.UpsideScore 5.4/10#10 of 25 Diagnostics & Research
Stop $244.81Target $279.05(analyst − 10%)A.R:R 1.6:1
Analyst target$310.06+21.2%17 analysts
$279.05our TP
$255.89price
$310.06mean
$347

Sell if holding. Momentum 1.3/10 is below the 5.0 floor at $255.89 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Thin upside margin: 9.0%. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.4/10, moderate confidence.

Passes 5/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on weak momentum. Suitability: moderate.

Thesis

Rewards
Strong earnings beat streak (4/4)
Risks
Thin upside margin: 9.0%
Negative momentum

Key Metrics

P/E (TTM)22.7
P/E (Fwd)13.3
Mkt Cap$21.1B
EV/EBITDA12.2
Profit Mgn6.7%
ROE11.0%
Rev Growth5.8%
Beta
Dividend1.12%
Rating analysts29

Quality Signals

Piotroski F7/9

Options Flow

P/C0.53bullish
IV44%normal
Max Pain$370+44.6% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMGeographicnon-U.S. operations
    10-K Item 1A: 'BLS derives a significant portion of its revenues from non-U.S. operations'

Material Events(8-K, last 90d)

  • 2026-02-09Item 5.02LOW
    John H. Sampson, M.D., Ph.D. (vice chancellor, University of Colorado Anschutz) appointed to Board effective February 9, 2026; assigned to Quality and Compliance Committee. Standard director compensation.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Volume
0.0
Obv
1.0
Ma Position
2.2
Rsi
3.5
Volume distribution (falling OBV)Below 200-MA but MA still rising (+0.6%/30d) — pullback in uptrend, not confirmed weakness

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
2.4
Quality Rank
4.3
Value Rank
8.0
GatesMomentum 1.3<4.5A.R:R 1.6 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARSuitability: Moderate
RSI
38 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $252.38Resistance $279.71

Price Targets

$245
$279
A.Upside+9.1%
A.R:R1.6:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Momentum score 1.3/10 — below 4.5 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-04-30 (nulld)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is LH stock a buy right now?

Sell if holding. Momentum 1.3/10 is below the 5.0 floor at $255.89 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Thin upside margin: 9.0%. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $244.81. Score 5.4/10, moderate confidence.

What is the LH stock price target?

Take-profit target: $279.05 (+9.0% upside). Prior stop was $244.81. Stop-loss: $244.81.

What are the risks of investing in LH?

Thin upside margin: 9.0%; Negative momentum.

Is LH overvalued or undervalued?

Labcorp Holdings Inc. trades at a P/E of 22.7 (forward 13.3). TrendMatrix value score: 6.9/10. Verdict: Sell.

What do analysts say about LH?

29 analysts cover LH with a consensus score of 4.1/5. Average price target: $310.

What does Labcorp Holdings Inc. do?Labcorp Holdings is a global laboratory services company with nearly 71,000 employees serving approximately 100...

Labcorp Holdings is a global laboratory services company with nearly 71,000 employees serving approximately 100 countries, performing 750M+ tests annually in 2025. Revenue is from diagnostic testing (Dx) billed to third-party payors and biopharma laboratory services (BLS) supporting pharmaceutical R&D. Supported more than 85%% of FDA-approved new drugs in 2025.

Related stocks: IQV (IQVIA Holdings, Inc.) · QGEN (Qiagen N.V.) · GH (Guardant Health, Inc.) · ILMN (Illumina, Inc.) · SHC (Sotera Health Company)